IONS vs SYRE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SYRE Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | SYRE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $9.8B | Larger Scale | SYRE |
| Trailing P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Revenue Growth (YoY) Growth | +54.9% | +0.0% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -58.8% | 0.0% | Higher Margin | SYRE |
| Net Profit Margin Profitability | -56.9% | 0.0% | Higher Margin | SYRE |
| Return on Equity (ROE) Capital Efficiency | -108.0% | -35.0% | Higher ROE | SYRE |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 88% ($22โ$111) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 1.75ฮฒ ยท 59% Vol | Lower Realized Risk | SYRE |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 44.4 / 100 (HOLD) | Higher Composite | IONS |